» Articles » PMID: 10989246

Prevalence and Characteristics of Breakthrough Pain in Cancer Patients Admitted to a Hospice

Overview
Publisher Elsevier
Date 2000 Sep 16
PMID 10989246
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

A prospective survey was undertaken to determine the prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. Of 414 consecutive admissions, 33 patients were confused or too unwell to take part and 136 were pain-free. The remaining 245 reported 404 pains (range 1-5 per patient); of these patients, 218 (89%) had breakthrough pain and identified 361 pains (range 1-5 per patient). Breakthrough pain was classified as somatic (46%) visceral (30%), neuropathic (10%) or mixed etiology (16%). Thirty-eight percent of pains were severe or excruciating. The average number of daily breakthrough pain episodes was 4 [corrected] (range 1-14); 49% occurred suddenly. Most (59%) were unpredictable, and 72% lasted less than 30 minutes. Seventy-five percent of patients were dissatisfied with their pain control. Breakthrough pain is common among patients admitted to our hospice. It is frequent, short lasting, often unpredictable and not necessarily related to chronic pain making treatment difficult.

Citing Articles

Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.

Chiang Y, Lien C, Su W, Yen T, Chen Y, Lai Y BMC Palliat Care. 2024; 23(1):150.

PMID: 38877477 PMC: 11177451. DOI: 10.1186/s12904-024-01483-7.


Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.

Tekie Y, Nigatu Y, Mekonnen W, Berhe Y Front Oncol. 2024; 13:1248921.

PMID: 38264754 PMC: 10805268. DOI: 10.3389/fonc.2023.1248921.


Assessing the feasibility, acceptability, and preliminary efficacy of a novel symptom management care delivery intervention for caregivers receiving home hospice care: The I-HoME protocol.

Phongtankuel V, Czaja S, Park T, Dignam R, Adelman R, Shah S Contemp Clin Trials. 2023; 136:107389.

PMID: 37972753 PMC: 10922463. DOI: 10.1016/j.cct.2023.107389.


Once again... breakthrough cancer pain: an updated overview.

Mercadante S J Anesth Analg Crit Care. 2023; 3(1):23.

PMID: 37480136 PMC: 10360268. DOI: 10.1186/s44158-023-00101-x.


Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.

Bossi P, Escobar Y, Pea F Front Pain Res (Lausanne). 2022; 3:893530.

PMID: 35721659 PMC: 9204512. DOI: 10.3389/fpain.2022.893530.